NCT05947669 Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis Status RECRUITING Phase PHASE3
NCT05931458 AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis Status NOT_YET_RECRUITING Phase NA
NCT05906576 Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Status RECRUITING Phase PHASE4
NCT05813860 HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease Status NOT_YET_RECRUITING Phase PHASE4
NCT05759104 Treatment and Fate in Fistulizing Crohn's Disease in a Pediatric Population Status UNKNOWN Phase N/A
NCT05660746 Precise Infliximab Exposure and Pharmacodynamic Control Status RECRUITING Phase PHASE2/PHASE3
NCT05552287 Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease Status RECRUITING Phase PHASE4
NCT05406934 Evaluation of Blood Platelet Indices,Platelet Aggregation in the Activity of IBD Patients on Biological Treatment Status UNKNOWN Phase N/A
NCT05386290 A Multicentered Prospective Cohort Study of Chinese IBD Patients Status UNKNOWN Phase N/A
NCT05291039 Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. Status COMPLETED Phase NA
NCT05280405 Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study Status UNKNOWN Phase PHASE4
NCT05205603 Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis Status COMPLETED Phase PHASE4
NCT05168475 Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Status TERMINATED Phase PHASE2
NCT05034536 PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE2